<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01416415</url>
  </required_header>
  <id_info>
    <org_study_id>NU 00051931</org_study_id>
    <nct_id>NCT01416415</nct_id>
  </id_info>
  <brief_title>Glaucoma Eye Drop Instillation: Impact of Education</brief_title>
  <official_title>Glaucoma Eye Drop Instillation: Impact of Education</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether an educational intervention will have a
      positive effect on patients' ability to properly administer eye drops. The investigators
      predict that the educational intervention will have a positive impact on the efficacy,
      safety, and efficiency with which patients administer their eye drops.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glaucoma is a leading cause of irreversible vision loss worldwide, and as such has a large
      public health impact. The only treatment proven to slow or arrest the progression of the
      disease process is intraocular pressure (IOP) reduction, which relies heavily on patient
      cooperation. Previously, nonadherence to glaucoma medications has ranged from 24% to 59%.
      Barriers to medication compliance in the glaucoma patient population include health literacy,
      poor comprehension of disease, poor comprehension of medication regimen, and improper eye
      drop administration technique. The purpose of this randomized, controlled clinical trial is
      to assess whether an educational intervention will have a positive effect on patients'
      ability to properly administer eye drops. Patients randomized to the experimental group will
      receive the educational intervention, consisting of an instructional video demonstrating how
      to instill eyedrops. Patients randomized to the control group will receive an attention
      placebo, consisting of a video regarding healthy eating tips. Additional measures that will
      be obtained from all patients include a health literacy score, as measured using the REALM
      questionnaire, and a BMQ - specific score (Beliefs about Medicines Questionnaire) using the
      BMQ-specific questionnaire. If the education protocol is found to positively affect eye drop
      administration success, as demonstrated by a statistically significant difference between the
      experimental and control groups, suggestions will be proposed for the implementation of
      educational programs similar to ours to improve glaucoma patient outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not practical to continue due interim results
  </why_stopped>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eye drop instillation score</measure>
    <time_frame>4 +/- 3 months</time_frame>
    <description>The eye drop instillation score is a composite score of the efficacy, safety, and efficiency with which the subject instills their eyedrops and is simply a measure of how well the subject administers their eyedrops.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <arm_group>
    <arm_group_label>Educational intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The educational intervention arm will contain subjects who will watch a video on proper eye drop instillation technique.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Attention placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The attention control placebo group will receive an educational intervention that mimics the amount of time and attention received by the treatment group. The video chosen is regarding healthy eating tips.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Video education on proper eye drop instillation technique</intervention_name>
    <description>The video is approximately seven minutes long and teaches the Robert Ritch method of instilling eye drops.</description>
    <arm_group_label>Educational intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo video education on healthy eating tips</intervention_name>
    <description>The video is approximately seven minutes long and teaches tips to promote healthy eating.</description>
    <arm_group_label>Attention placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established care with the treating ophthalmologist for at least 6 months

          -  Diagnosis of open-angle glaucoma or ocular hypertension

          -  The use of one, two or three self-instilled eye drop medications in one or two eyes

          -  Age 40-85 years

          -  Fluency in English

          -  Best corrected visual acuity (BCVA) of 20/50 or better in each eye

        Exclusion Criteria:

          -  Presence of moderate to severe cognitive deficits

          -  Presence of a clinically significant tremor

          -  Mini Mental Status Exam score â‰¤ 20
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelo P Tanna, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University Department of Ophthalmology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Medical Faculty Foundation</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kulkarni SV, Damji KF, Buys YM. Medical management of primary open-angle glaucoma: Best practices associated with enhanced patient compliance and persistency. Patient Prefer Adherence. 2008 Feb 2;2:303-14.</citation>
    <PMID>19920977</PMID>
  </reference>
  <reference>
    <citation>Nemesure B, Honkanen R, Hennis A, Wu SY, Leske MC; Barbados Eye Studies Group. Incident open-angle glaucoma and intraocular pressure. Ophthalmology. 2007 Oct;114(10):1810-5. Epub 2007 Jun 20.</citation>
    <PMID>17583352</PMID>
  </reference>
  <reference>
    <citation>The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol. 2000 Oct;130(4):429-40.</citation>
    <PMID>11024415</PMID>
  </reference>
  <reference>
    <citation>Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30.</citation>
    <PMID>12049574</PMID>
  </reference>
  <reference>
    <citation>The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998 Oct;126(4):498-505.</citation>
    <PMID>9780094</PMID>
  </reference>
  <reference>
    <citation>Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, Mills RP; CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001 Nov;108(11):1943-53.</citation>
    <PMID>11713061</PMID>
  </reference>
  <reference>
    <citation>Gold DT, McClung B. Approaches to patient education: emphasizing the long-term value of compliance and persistence. Am J Med. 2006 Apr;119(4 Suppl 1):S32-7. Review.</citation>
    <PMID>16563940</PMID>
  </reference>
  <reference>
    <citation>Vakil N. Increasing compliance with long-term therapy: avoiding complications and adverse events. Rev Gastroenterol Disord. 2005;5 Suppl 2:S12-7. Review.</citation>
    <PMID>16369223</PMID>
  </reference>
  <reference>
    <citation>Gurwitz JH, Glynn RJ, Monane M, Everitt DE, Gilden D, Smith N, Avorn J. Treatment for glaucoma: adherence by the elderly. Am J Public Health. 1993 May;83(5):711-6.</citation>
    <PMID>8484454</PMID>
  </reference>
  <reference>
    <citation>Schwartz GF. Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol. 2005 Apr;16(2):114-21. Review.</citation>
    <PMID>15744142</PMID>
  </reference>
  <reference>
    <citation>Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003 Oct;12(5):393-8.</citation>
    <PMID>14520147</PMID>
  </reference>
  <reference>
    <citation>Rotchford AP, Murphy KM. Compliance with timolol treatment in glaucoma. Eye (Lond). 1998;12 ( Pt 2):234-6.</citation>
    <PMID>9683946</PMID>
  </reference>
  <reference>
    <citation>Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995 May-Jun;26(3):233-6.</citation>
    <PMID>7651690</PMID>
  </reference>
  <reference>
    <citation>Dietlein TS, Jordan JF, LÃ¼ke C, Schild A, Dinslage S, Krieglstein GK. Self-application of single-use eyedrop containers in an elderly population: comparisons with standard eyedrop bottle and with younger patients. Acta Ophthalmol. 2008 Dec;86(8):856-9. doi: 10.1111/j.1755-3768.2007.01155.x. Epub 2008 May 20.</citation>
    <PMID>18494743</PMID>
  </reference>
  <reference>
    <citation>Djafari F, Lesk MR, Harasymowycz PJ, Desjardins D, Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009 Mar;18(3):238-43. doi: 10.1097/IJG.0b013e3181815421.</citation>
    <PMID>19295380</PMID>
  </reference>
  <reference>
    <citation>Gelb L, Friedman DS, Quigley HA, Lyon DW, Tan J, Kim EE, Zimmerman TJ, Hahn SR. Physician beliefs and behaviors related to glaucoma treatment adherence: the Glaucoma Adherence and Persistency Study. J Glaucoma. 2008 Dec;17(8):690-8. doi: 10.1097/IJG.0b013e31816b3001.</citation>
    <PMID>19092468</PMID>
  </reference>
  <reference>
    <citation>Friedman DS, Hahn SR, Quigley HA, Kotak S, Kim E, Onofrey M, Eagan C, Mardekian J. Doctor-patient communication in glaucoma care: analysis of videotaped encounters in community-based office practice. Ophthalmology. 2009 Dec;116(12):2277-85.e1-3. doi: 10.1016/j.ophtha.2009.04.052. Epub 2009 Sep 10.</citation>
    <PMID>19744715</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2011</study_first_submitted>
  <study_first_submitted_qc>August 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2011</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Angelo Tanna</investigator_full_name>
    <investigator_title>Vice Chairman, Department of Ophthalmology and Director, Glaucoma Service</investigator_title>
  </responsible_party>
  <keyword>Glaucoma, Open-Angle</keyword>
  <keyword>Ophthalmic Solutions, Eye drops</keyword>
  <keyword>Instructional Films and Videos</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

